666830-86-0

Basic information

• Product Name: 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1,5-dihydro-5-[(phenylmethoxy)methyl]-7-[[(3R,4R)-3-(phenylmethoxy)-4 -[(phenylmethoxy)methyl]-1-pyrrolidinyl]methyl]-
• CAS NO: 666830-86-0
• Molecular Formula: C34H36N4O4
• Molecular Weight: 564.684
• Mol File: 666830-86-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1,5-dihydro-5-[(phenylmethoxy)methyl]-7-[[(3R,4R)-3-(phenylmethoxy)-4 -[(phenylmethoxy)methyl]-1-pyrrolidinyl]methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1,5-dihydro-5-[(phenylmethoxy)methyl]-7-[[(3R,4R)-3-(phenylmethoxy)-4 -[(phenylmethoxy)methyl]-1-pyrrolidinyl]methyl]-(666830-86-0)
• EPA Substance Registry System: 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1,5-dihydro-5-[(phenylmethoxy)methyl]-7-[[(3R,4R)-3-(phenylmethoxy)-4 -[(phenylmethoxy)methyl]-1-pyrrolidinyl]methyl]-(666830-86-0)

Safety Data

• Hazardous Substances Data: 666830-86-0(Hazardous Substances Data)

Upstream product

• 635319-15-2 7-(3-benzyloxy-4-benzyloxymethyl-pyrrolidin-1-ylmethyl)-5-benzyloxymethyl-4-tert-butoxy-5H-pyrrolo[3,2-d]pyrimidine 
• 635319-10-7 (3R,4R)-N-tert-butoxycabonyl-3-benzyloxy-4-benzyloxymethylpyrrolidine 
• 635319-12-9 7-benzyloxymethyl-6-O-tert-butyl-9-deaza-9-formylhypoxanthine 
• 635319-09-4 tert-butyl (3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 299916-78-2 7-N-benzyloxymethyl-9-bromo-6-O-tert-butyl-9-deaza-hypoxanthine 

Downstream Products

• 666830-87-1 (3R,4R)-1-[(9-deaza-7-benzyloxymethyl-adenin-9-yl)methyl]-3-benzyloxy-4-(benzyloxymethyl)pyrrolidine 

Relevant articles and documents

INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES

The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5'-methylthioadenosine phosphorylases (MTAP), 5'-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds